Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on June 18, 2025
NY Top Docs Honors Dr. Azeem Khan as a 2025 Top Doctor
EIN Presswire
·
June 18, 2025
Dr. Azeem Khan has been reviewed and approved by NY Top Docs based on merit for 2025 FOREST HILLS, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- Dr. Azeem Khan is a skilled Interventional Gastroenterologist with over 25 years of experience in …
Three-Dimensional Upgrade: Creative Biolabs Advances Antibody Engineering and Therapeutics
EIN Presswire
·
June 18, 2025
Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- Immunogenicity has long been a major bottleneck …
JUARA Launches Miracle Tea Recovery Crème: Skin Support Through Life’s Natural Transitions
EIN Presswire
·
June 18, 2025
JUARA, the skincare brand inspired by ancient Indonesian wellness traditions, recently launched their newest product: Miracle Tea Recovery Crème. NEW YORK, NY, UNITED STATES, June 17, 2025 /EINPresswire.com/ -- JUARA, the skincare brand inspired by …
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.
GlobeNewswire
·
June 18, 2025
KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian Nordic blev tildelt voucheren i februar 2025 i forbindelse …
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
GlobeNewswire
·
June 18, 2025
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in …
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
GlobeNewswire
·
June 18, 2025
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will …
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
GlobeNewswire
·
June 18, 2025
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative treatments Proceeds will fund four clinical studies: two related to the …
Biomea Fusion Announces Pricing of Public Offering of Securities
GlobeNewswire
·
June 18, 2025
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19, …
Participation in “The 113th Congress of Japan Society of Aesthetic Surgery,” May 2025
GlobeNewswire
·
June 18, 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”) today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty …
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42
GlobeNewswire
·
June 18, 2025
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its …